Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension. Huang C, Bai J, Luo A, Yang L, et al. Hypertension 2026 Jul 27. doi: 10.1161/HYPERTENSIONAHA.126.26711.

Read + Share

Amedeo Smart

Independent Medical Education

Huang C, Bai J, Luo A, Yang L, et al. Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension. Hypertension 2026 Jul 27. doi: 10.1161/HYPERTENSIONAHA.126.26711.
PMID: 42504621